Literature DB >> 29713898

Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity.

Vivian Y Chang1,2, Jessica J Wang3.   

Abstract

PURPOSE OF REVIEW: The goal of this review is to summarize current understanding of pharmacogenetics and pharmacogenomics in chemotherapy-induced cardiotoxicity. RECENT
FINDINGS: Most of the studies rely on in vitro cytotoxic assays. There have been several smaller scale candidate gene approaches and a handful of genome-wide studies linking genetic variation to susceptibility to chemotherapy-induced cardiotoxicity. Currently, pharmacogenomic testing of all childhood cancer patients with an indication for doxorubicin or daunorubicin therapy for RARG rs2229774, SLC28A3 rs7853758, and UGT1A6*4 rs17863783 variants is recommended. There is no recommendation regarding testing in adults. There is clear evidence pointing to the role of pharmacogenetics and pharmacogenomics in cardiotoxicity susceptibility to chemotherapeutic agents. Larger scale studies are needed to further identify susceptibility markers and to develop pharmacogenomics-based risk profiling to improve quality of life and life expectancy in cancer survivors.

Entities:  

Keywords:  Chemotherapy-induced cardiomyopathy; Chemotherapy-induced cardiotoxicity; Pharmacogenetics of cancer; Pharmacogenomics of cancer

Mesh：

Substances：

Year:  2018        PMID： 29713898      PMCID： PMC6371783          DOI： 10.1007/s11912-018-0696-8

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  73 in total

1.  Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil.

Authors:  E Van Cutsem; P M Hoff; J L Blum; M Abt; B Osterwalder
Journal:  Ann Oncol       Date:  2002-03       Impact factor: 32.976

2.  Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity.

Authors:  M Eileen Dolan; Karla G Newbold; Ramamoorthy Nagasubramanian; Xiaolin Wu; Mark J Ratain; Edwin H Cook; Judith A Badner
Journal:  Cancer Res       Date:  2004-06-15       Impact factor: 12.701

Review 3.  The cardiac safety of trastuzumab in the treatment of breast cancer.

Authors:  A Jo Chien; Hope S Rugo
Journal:  Expert Opin Drug Saf       Date:  2010-03       Impact factor: 4.250

4.  5-fluorouracil induced cardiotoxicity in albino rats.

Authors:  S Kumar; R K Gupta; N Samal
Journal:  Mater Med Pol       Date:  1995 Apr-Jun

Review 5.  HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways.

Authors:  Xiao-Feng Le; Franz Pruefer; Robert C Bast
Journal:  Cell Cycle       Date:  2005-01-10       Impact factor: 4.534

6.  Capecitabine-related cardiotoxicity: recognition and management.

Authors:  Muhammad Wasif Saif; Megumi Tomita; Leslie Ledbetter; Robert B Diasio
Journal:  J Support Oncol       Date:  2008-01

Review 7.  Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.

Authors:  Folefac Aminkeng; Colin J D Ross; Shahrad R Rassekh; Soomi Hwang; Michael J Rieder; Amit P Bhavsar; Anne Smith; Shubhayan Sanatani; Karen A Gelmon; Daniel Bernstein; Michael R Hayden; Ursula Amstutz; Bruce C Carleton
Journal:  Br J Clin Pharmacol       Date:  2016-06-30       Impact factor: 4.335

Review 8.  A reassessment of cardiac toxicity associated with Taxol.

Authors:  S G Arbuck; H Strauss; E Rowinsky; M Christian; M Suffness; J Adams; M Oakes; W McGuire; E Reed; H Gibbs
Journal:  J Natl Cancer Inst Monogr       Date:  1993

Review 9.  Update on angiogenesis inhibitors.

Authors:  Anaadriana Zakarija; Gerald Soff
Journal:  Curr Opin Oncol       Date:  2005-11       Impact factor: 3.645

10.  A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.

Authors:  Folefac Aminkeng; Amit P Bhavsar; Henk Visscher; Shahrad R Rassekh; Yuling Li; Jong W Lee; Liam R Brunham; Huib N Caron; Elvira C van Dalen; Leontien C Kremer; Helena J van der Pal; Ursula Amstutz; Michael J Rieder; Daniel Bernstein; Bruce C Carleton; Michael R Hayden; Colin J D Ross
Journal:  Nat Genet       Date:  2015-08-03       Impact factor: 38.330
View more
  15 in total

Review 1.  Cardiovascular diseases in survivors of childhood cancer.

Authors:  Neha Bansal; Javier G Blanco; Umesh C Sharma; Saraswati Pokharel; Shannon Shisler; Steven E Lipshultz
Journal:  Cancer Metastasis Rev       Date:  2020-03       Impact factor: 9.264

Review 2.  Cardio-Oncology in Childhood: State of the Art.

Authors:  Elena Bennati; Francesca Girolami; Gaia Spaziani; Giovanni Battista Calabri; Claudio Favre; Iris Parrini; Fabiana Lucà; Angela Tamburini; Silvia Favilli
Journal:  Curr Oncol Rep       Date:  2022-10-01       Impact factor: 5.945

3.  State of Knowledge on Molecular Adaptations to Exercise in Humans: Historical Perspectives and Future Directions.

Authors:  Kaleen M Lavin; Paul M Coen; Liliana C Baptista; Margaret B Bell; Devin Drummer; Sara A Harper; Manoel E Lixandrão; Jeremy S McAdam; Samia M O'Bryan; Sofhia Ramos; Lisa M Roberts; Rick B Vega; Bret H Goodpaster; Marcas M Bamman; Thomas W Buford
Journal:  Compr Physiol       Date:  2022-03-09       Impact factor: 8.915

Review 4.  New Insights on the Toxicity on Heart and Vessels of Breast Cancer Therapies.

Authors:  Oreste Lanza; Armando Ferrera; Simone Reale; Giorgio Solfanelli; Mattia Petrungaro; Giacomo Tini Melato; Massimo Volpe; Allegra Battistoni
Journal:  Med Sci (Basel)       Date:  2022-05-25

5.  Effects of genetic polymorphisms on the sulfation of doxorubicin by human SULT1C4 allozymes.

Authors:  Saud A Gohal; Mohammed I Rasool; Ahsan F Bairam; Eid S Alatwi; Fatemah A Alherz; Maryam S Abunnaja; Amal A El Daibani; Katsuhisa Kurogi; Ming-Cheh Liu
Journal:  J Biochem       Date:  2021-10-12       Impact factor: 3.387

Review 6.  Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection.

Authors:  Marco Bruno Morelli; Chiara Bongiovanni; Silvia Da Pra; Carmen Miano; Francesca Sacchi; Mattia Lauriola; Gabriele D'Uva
Journal:  Front Cardiovasc Med       Date:  2022-04-15

7.  Is it possible to prevent chemotherapy-induced heart failure with cardiovascular drugs - the review of the current clinical evidence.

Authors:  Katarzyna Korzeniowska; Jerzy Jankowski; Artur Cieślewicz; Anna Jabłecka
Journal:  Ther Clin Risk Manag       Date:  2019-09-09       Impact factor: 2.423

8.  Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children's Oncology Group.

Authors:  Kelly D Getz; Lillian Sung; Bonnie Ky; Robert B Gerbing; Kasey J Leger; Allison Barz Leahy; Leah Sack; William G Woods; Todd Alonzo; Alan Gamis; Richard Aplenc
Journal:  J Clin Oncol       Date:  2018-10-31       Impact factor: 50.717

9.  Protective Effect of Methylxanthine Fractions Isolated from Bancha Tea Leaves against Doxorubicin-Induced Cardio- and Nephrotoxicities in Rats.

Authors:  Maya P Radeva-Ilieva; Kaloyan D Georgiev; Nadezhda R Hvarchanova; Stanila S Stoeva; Iliya J Slavov; Deyan L Dzhenkov; Marieta P Georgieva
Journal:  Biomed Res Int       Date:  2020-08-11       Impact factor: 3.411

Review 10.  Combinatorial Therapies in Thyroid Cancer: An Overview of Preclinical and Clinical Progresses.

Authors:  Gheysen Laetitia; Saussez Sven; Journe Fabrice
Journal:  Cells       Date:  2020-03-30       Impact factor: 6.600
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.